MAPK1 and cardiac hypertrophy: We modeled optimal pharmacological intervention points that are beneficial for the heart, but avoid the occurrence of a maladaptive ERK1/2 modification, the autophosphorylation of ERK at threonine 188 (ERKThr188 phosphorylation), which causes cardiac hypertrophy.